Home › Compare › PTAIF vs ABBV
PTAIF yields 6.01% · ABBV yields 3.06%● Live data
📍 PTAIF pulled ahead of the other in Year 1
Combined, PTAIF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of PTAIF + ABBV for your $10,000?
PT Astra International Tbk, together with its subsidiaries, operates in the automotive, financial services, heavy equipment, mining, construction, energy, agri, infrastructure and logistics, information technology, and property businesses in Indonesia. It offers cars, trucks, and motorcycles of various brands; manufactures and sells automotive components to the original equipment for manufacturers and replacement markets, as well as provides consultation services to its customers; financing for cars, motorcycles, and heavy equipment; life, vehicle, and health insurance, as well as other insurance for commercial business; and various banking products and services. The company also distributes heavy equipment for the mining, plantation, construction, forestry, transportation, and material handling industries; provides coal mining contracting services; operates coal mines; and produces crude palm oil. In addition, it is involved in the operation of toll roads; rental of vehicles; sale of used cars; and provision of logistics and warehousing services, as well as freight forwarding service through ground, sea, and air transportation. Further, the company offers various information technology business solutions based on document, information, and communication technology; and engages in the property development and management activities. Additionally, it is involved in the foundation; formwork and bekisting; pump services; and mechanical, electrical, and plumbing works. The company was incorporated in 1957 and is headquartered in Jakarta, Indonesia. PT Astra International Tbk is a subsidiary of Jardine Cycle & Carriage Limited.
Full PTAIF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.